Open Label Continuation Study in Moderate to Severe Psoriasis

Study Identifier
M10-016
CT.gov Identifier
NCT00626002
EudraCT Identifier
2007-005955-40
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Dermatology - Psoriasis (PsO)
    • Study Drug
  • ABT-874
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Having participated in a preceding ABT-874 clinical trial for ABT-874 * Subject has a clinical diagnosis of moderate to severe plaque psoriasis
    Exclusion Criteria:
    * Subjects who prematurely discontinued in any preceding psoriasis study with ABT-874 other than protocol-required discontinuation

    Protocol Summary

    The purpose of this study is to evaluate long term safety, efficacy and tolerability of ABT-874 in adults with moderate to severe psoriasis.

    Study Locations

    Location
    Status
    Location
    Site Reference ID/Investigator# 7496
    Birmingham, Alabama, United States, 35205
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 8438
    Birmingham, Alabama, United States, 35233
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 7522
    Huntsville, Alabama, United States, 35801
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 7774
    Scottsdale, Arizona, United States, 85251
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 7435
    Tucson, Arizona, United States, 85710
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 7933
    Little Rock, Arkansas, United States, 72204
    Status
    Not applicable
    Showing {first} - {last} of {total} Results